
Wendy E Heywood

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8189646/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early downregulation of hsa-miR-144-3p in serum from drug-naÃ⁻ve Parkinson's disease patients. Scientific Reports, 2022, 12, 1330.	3.3	14
2	Tissue Proteome of 2-Hydroxyacyl-CoA Lyase Deficient Mice Reveals Peroxisome Proliferation and Activation of ω-Oxidation. International Journal of Molecular Sciences, 2022, 23, 987.	4.1	4
3	Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients. Npj Parkinson's Disease, 2022, 8, 14.	5.3	11
4	Urine proteomics analysis of patients with neuronal ceroid lipofuscinoses. IScience, 2021, 24, 102020.	4.1	12
5	A geroscience approach for Parkinson's disease: Conceptual framework and design of PROPAG-AGEING project. Mechanisms of Ageing and Development, 2021, 194, 111426.	4.6	14
6	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 2021, 10, 614.	1.6	4
7	Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients. Npj Parkinson's Disease, 2021, 7, 78.	5.3	2
8	Proteomic signatures for perioperative oxygen delivery in skin after major elective surgery: mechanistic sub-study of a randomised controlled trial. British Journal of Anaesthesia, 2021, 127, 511-520.	3.4	2
9	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. Molecular and Cellular Proteomics, 2020, 19, 114-127.	3.8	32
10	Applying modern Omic technologies to the Neuronal Ceroid Lipofuscinoses. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165498.	3.8	17
11	Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease. Journal of Medical Genetics, 2020, 57, 38-47.	3.2	26
12	Free urinary glycosylated hydroxylysine as an indicator of altered collagen degradation in the mucopolysaccharidoses. Journal of Inherited Metabolic Disease, 2020, 43, 309-317.	3.6	10
13	An InÂVitro Whole-Organ Liver Engineering for Testing of Genetic Therapies. IScience, 2020, 23, 101808.	4.1	8
14	Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations. JAMA Neurology, 2020, 77, 427.	9.0	213
15	Investigation of pathology, expression and proteomic profiles in human <i>TREM2</i> variant postmortem brains with and without Alzheimer's disease. Brain Pathology, 2020, 30, 794-810.	4.1	10
16	â€~The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research, 2020, 9, 1349.	1.6	95
17	â€~The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Research, 2020, 9, 1349.	1.6	116
18	Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2726-2735.	3.8	13

WENDY E HEYWOOD

#	Article	lF	CITATIONS
19	An Optimized Method for the Proteomic Analysis of Low Volumes of Cell Culture Media and the Secretome: The Application and the Demonstration of Altered Protein Expression in iPSC-Derived Neuronal Cell Lines from Parkinson's Disease Patients. Journal of Proteome Research, 2019, 18, 1198-1207.	3.7	2
20	Preparation of iPSCs for Targeted Proteomic Analysis. Methods in Molecular Biology, 2019, 1994, 131-139.	0.9	1
21	Mass Spectrometry Measurement of Albumin–Alpha Fetoprotein Ratio as an Indicator of iPSC-Derived Hepatocyte Differentiation. Methods in Molecular Biology, 2019, 1994, 149-156.	0.9	0
22	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, e001974.	3.6	38
23	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circulation Genomic and Precision Medicine, 2018, 11, .	3.6	34
24	Reproducibility of Molecular Phenotypes after Long-Term Differentiation toÂHuman iPSC-Derived Neurons: A Multi-Site Omics Study. Stem Cell Reports, 2018, 11, 897-911.	4.8	135
25	CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2018, 72, 171-176.	3.1	25
26	Comparative proteomic analysis of normal and gliotic PVR retina and contribution of Müller glia to this profile. Experimental Eye Research, 2018, 177, 197-207.	2.6	17
27	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. Acta Neuropathologica Communications, 2018, 6, 62.	5.2	9
28	A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid. Neuromethods, 2018, , 169-177.	0.3	0
29	Multiplex High-Throughput Targeted Proteomic Assay To Identify Induced Pluripotent Stem Cells. Analytical Chemistry, 2017, 89, 2440-2448.	6.5	15
30	Comparison of proteomic profiles in the zebrafish retina during experimental degeneration and regeneration. Scientific Reports, 2017, 7, 44601.	3.3	20
31	Proteomic profiling reveals sub proteomes of the human placenta. Placenta, 2017, 59, 69-72.	1.5	7
32	Regulation of post-Golgi LH3 trafficking is essential for collagen homeostasis. Nature Communications, 2016, 7, 12111.	12.8	54
33	A rapid high throughput proteomic method based on profiling of proteolytic free peptides to assess post-delivery degradation of placental tissue. Placenta, 2016, 44, 109-111.	1.5	0
34	An unforgettable change of perspective. British Journal of Nursing, 2016, 25, 509-509.	0.7	0
35	An optimised method for the proteomic profiling of full thickness human skin. Biological Procedures Online, 2016, 18, 15.	2.9	23
36	Global serum glycoform profiling for the investigation of dystroglycanopathies & Congenital Disorders of Glycosylation. Molecular Genetics and Metabolism Reports, 2016, 7, 55-62.	1.1	8

Wendy E Heywood

#	Article	IF	CITATIONS
37	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Molecular Neurodegeneration, 2016, 11, 3.	10.8	236
38	A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status. Journal of Visualized Experiments, 2016, , .	0.3	2
39	Proteomic Discovery and Development of a Multiplexed Targeted MRM-LC-MS/MS Assay for Urine Biomarkers of Extracellular Matrix Disruption in Mucopolysaccharidoses I, II, and VI. Analytical Chemistry, 2015, 87, 12238-12244.	6.5	20
40	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	10.8	121
41	The development of a rapid, multiplexed UPLC–MS/MS assay for quantitation of lyso-Gb3 and Gb3 in dried blood spots. Molecular Genetics and Metabolism, 2015, 114, S107.	1.1	0
42	Current applications of biomarkers in cardiomyopathies. Expert Review of Cardiovascular Therapy, 2015, 13, 825-837.	1.5	13
43	Growth associated protein (GAP-43): Cloning and the development of a sensitive ELISA for neurological disorders. Journal of Neuroimmunology, 2014, 276, 18-23.	2.3	6
44	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. Blood, 2014, 124, 3808-3816.	1.4	19
45	Progression in multiple sclerosis is associated with low endogenous <scp>NCAM</scp> . Journal of Neurochemistry, 2013, 125, 766-773.	3.9	14
46	A New Method for the Rapid Diagnosis of Protein N-linked Congenital Disorders of Glycosylation. Journal of Proteome Research, 2013, 12, 3471-3479.	3.7	24
47	The Identification of New Biomarkers for Identifying and Monitoring Kidney Disease and Their Translation into a Rapid Mass Spectrometry-Based Test: Evidence of Presymptomatic Kidney Disease in Pediatric Fabry and Type-I Diabetic Patients. Journal of Proteome Research, 2013, 12, 2013-2021.	3.7	63
48	The development of a peptide SRM-based tandem mass spectrometry assay for prenatal screening of Down syndrome. Journal of Proteomics, 2012, 75, 3248-3257.	2.4	17
49	The identification of a new role for LEKTI in the skin: The use of protein †bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome. Journal of Proteomics, 2012, 75, 3925-3937.	2.4	11
50	Identification of new biomarkers for Down's syndrome in maternal plasma. Journal of Proteomics, 2012, 75, 2621-2628.	2.4	16
51	2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome. Proteome Science, 2011, 9, 56.	1.7	16
52	New Role for LEKTI in Skin Barrier Formation: Label-Free Quantitative Proteomic Identification of Caspase 14 as a Novel Target for the Protease Inhibitor LEKTI. Journal of Proteome Research, 2010, 9, 4289-4294.	3.7	41
53	Cytolethal distending toxin: creating a gap in the cell cycle. Journal of Medical Microbiology, 2005, 54, 207-216.	1.8	49
54	Mechanism of internalization of the cytolethal distending toxin of Actinobacillus actinomycetemcomitans. Microbiology (United Kingdom), 2005, 151, 1395-1402.	1.8	38

Wendy E Heywood

#	Article	IF	CITATIONS
55	Development of a Novel Targeting System for Lethal Photosensitization of Antibiotic-Resistant Strains of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2005, 49, 3690-3696.	3.2	95
56	Programming of defective rat pancreatic β-cell function in offspring from mothers fed a low-protein diet during gestation and the suckling periods. Clinical Science, 2004, 107, 37-45.	4.3	48
57	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. F1000Research, 0, 10, 614.	1.6	2
58	Niemann–Pick type C disease as proofâ€ofâ€concept for intelligent biomarker panel selection in neurometabolic disorders. Developmental Medicine and Child Neurology, 0, , .	2.1	6